Verification of an automated faecal elastase assay for use in NHS Lanarkshire
Daly et al.
Evaluation of the BÜHLMANN fPELA® turbo assay on the Beckman Coulter AU5822 automated chemistry analyser
H. Witham & N.J. Pullan
Patient extraction of faecal calprotectin at home does not significantly impact the currently used screening thresholds for inflammatory bowel disease
Clifford-Mobley et al.
Additional Literature
Overview
Quantum Blue® Therapeutic Drug Monitoring flyer
Successful Routine Use of Quantum Blue® Therapeutic Drug Monitoring (TDM) Assays in an Italian Children’s Hospital
An interview with Dr. ssa Giuliana Cangemi
Infliximab
Patient-near Infliximab trough-level testing by a novel quantitative rapid test: The Quantum Blue Infliximab test
Lindsjø et al.
Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays
Afonso J et al.
Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays
Afonso J et al.
First successful comparison of Quantum Blue® rapid TDM assay standardization with WHO international standard for infliximab
Keller et al.
Pharmacist-led proactive therapeutic drug monitoring with infliximab (PROXIMO): utility of and cost-saving with the use of a rapid assay for assessing drug level
C Rentsch et al.
Adulimumab
Patient-near Adalimumab trough-level testing by a novel quantitative rapid test: The Quantum Blue Adalimumab assay
Lindsjø et al.
Accuracy of the new rapid test for monitoring adalimumab levels
Rocha et al.